• Globe Newswire

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Globenewswire -

• Globe Newswire

JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)

Globenewswire -

• Globe Newswire

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Globenewswire -

• Globe Newswire

Pooled data presented at ERS: nerandomilast monotherapy linked to nominally significant reduction in risk of death in IPF and PPF

Globenewswire -

• Globe Newswire

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Globenewswire -

• Globe Newswire

Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis

Globenewswire -

• Globe Newswire

Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study